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The aim of this study was to investigate the impact of new insights and revised





The InterAction Database (IADB), which contains pharmacy dispensing data from 53
community pharmacies in the Northern and Eastern part of the Netherlands, was
used in this study. Prevalence and incidence rates of oral antihyperglycaemic drug
use were calculated for each year. Follow-up treatment was compared for two cohorts
of initial users of oral antihyperglycaemic drugs, star ting treatment either 1 year before




The prevalence and incidence rate of oral antihyperglycaemic drug use increased over













proportion of metformin as initial treatment increased rapidly in the observation






 0.001). Initial users of metformin in 2000 received
additional treatment with a sulphonylurea in the follow-up period less often compared












 0.004). In contrast,
initial users of sulphonylurea in 2000 received additional treatment with metformin












 0.008). The new drugs, thiazolidinediones and meglitinides, were seldom




New insights and the revision of the practice guideline were followed by a significant
increase in both initial and follow-up treatment with metformin among patients with




Diabetes mellitus is a growing disease largely accounted
for an increasing number of people diagnosed with Type









 is often started by a general practitioner
(GP). Changing lifestyle and dietary measures are usu-
ally the first step. The second step is pharmacotherapy
with an oral blood glucose-lowering drug. In the early
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1990s in the Netherlands, as in the rest of the world,
there were three groups of oral blood glucose-lowering





glucosidase-inhibitors. After 1999, two new groups of
drugs, i.e. meglitinides (repaglinide, nateglinide) and
thiazolidinediones (rosiglitazone, pioglitazone), became
available.
International and national guidelines provide evi-
dence-based recommendations for the treatment of
TD2M [1]. In the Netherlands, we have national practice
guidelines of the Dutch College of General Practitioners




appeared in 1989 and recommended to start with a
short-acting (or weak) sulphonylurea, such as tolbuta-




 patients. When the effect of tolbuta-
mide was insufficient, a switch was recommended to a
longer-acting (strong) sulphonylurea, such as gliclazide
or glibenclamide. The use of metformin was reserved










. The biguanide metformin was feared for its
risk of lactic acidosis and considered to be contraindi-
cated in patients with renal impairment or cardiovascu-





judged to be modestly effective, but hampered by a high
prevalence of gastrointestinal side-effects and recom-
mended only in combination with other drugs.
In September 1998, the United Kingdom Prospective
Diabetes Study (UKPDS) research group published the
results of intensified treatment of diabetes and demon-





 patients [4, 5]. Worldwide, the UKPDS results





the NHG guideline was thoroughly revised in line with
the results of the UKPDS study. In the revised guideline,
a distinction in pharmacological treatment was made for

















) were advised to start
initial treatment with a sulphonylurea, such as tolbuta-











) the recommendation was to start with metformin.
When monotherapy failed, a combination of metformin
and sulphonylurea was considered appropriate. The new
drugs, meglitinides and thiazolidinediones, were not yet
included in this revised guideline.
It is recognized that new guidelines or insights are not
always implemented in daily practice [6, 7]. From stud-
ies of drug prescription trends conducted in the USA
and UK, it has become clear that the use of metformin
and thiazolidinediones has increased since 1997 at the
expense of especially long-acting sulphonylurea [8–11].
These studies, however, did not provide insight into the
treatment steps at the level of the individual patient.
Therefore, it is not clear to what extent these drugs were
prescribed as initial or follow-up treatment. In this
study, we investigated the impact of revised insights and










The InterAction Database (IADB), containing phar-
macy dispensing data from 53 community pharmacies
in the Northern and Eastern part of the Netherlands, was
used in this study [12, 13]. In the period from 1997 to
2003, the IADB covered a population of approximately
450 000 people. The size of this population increased
over the study period but there was no change in age
and gender distribution. In the Netherlands, people com-
monly register with one pharmacy and obtain all their
medication from that pharmacy, so that a complete med-
ication history of an individual is available in the phar-
macy dispensing records.
The prevalence and incidence rates of oral antihyper-
glycaemic drug use (ATC code A10B*, Table 1) were









65 years) and gender. The
yearly prevalence rate was calculated by counting the
number of patients receiving one or more prescriptions
for an oral antihyperglycaemic drug divided by the total
number of patients in the database per age and gender
group in the respective years. The incidence rate of oral
antihyperglycaemic drug use was defined as the number
of people who received initial treatment with an oral
antihyperglycaemic drug per year.
From the population, we defined patients using anti-





. In this group, proportions of initial treatment
were calculated for every calendar year of the observa-
tion period. Initial treatment was defined as the first
prescription dispensed for an antihyperglycaemic drug
when no antihyperglycaemic drugs had been dispensed
in the preceding 6 months (in the Netherlands, drugs are
dispensed for a maximum of 3 months). When a patient
received two prescriptions for antihyperglycaemic drugs







 tests were used to determine differ-
ences between proportions.
To investigate changes in treatment during follow-up,
we followed two cohorts of initial users over a period
of 2.7 years (1000 days). The first cohort started an oral
antihyperglycaemic drug in 1998 and the second cohort
in 2000, one year before and one year after, respectively,
the introduction of the revised NHG guidelines. The
cohorts were divided into those starting with metformin
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(initial metformin group) and those starting with a sul-
phonylurea (initial sulphonylurea group). The cohorts
were separately evaluated for males and females. Data
were analysed using Kaplan–Meier survival (log-rank
tested) and Cox proportional hazard analyses. The event
in these analyses was the start of another antihypergly-
caemic drug (metformin, sulphonylurea or insulin),
either in addition to or as a replacement of the initial
drug. Survival time was censored for death or moving
(loss to follow-up) and follow-up period. Adjustments
for age differences (between the cohorts) were made
using Cox proportional hazard analyses. All statistical
analyses were performed using SPSS 12 statistical soft-




The prevalence and incidence rate of oral antihypergly-
caemic drug use increased in the study period (Table 2,







 0.001) and this change was similar for
males and females (Table 2). The incidence rate






 0.04). The incidence





almost zero, and not displayed.
The proportion of metformin as initial treatment
showed a large increase from 13.4% in 1998 to 49.9%








 0.001), consequently decreasing
the proportion of initial sulphonylurea use. Of the sul-
phonylureas, the use of gliclazide and glimepiride was
unchanged, whereas that of glibenclamide and tolbuta-
mide decreased. The use of other drugs, including acar-
bose, rosiglitazon, pioglitazon, repaglinide and insulin,
was very small as initial treatment. Finally, between 2
and 3% of the patients were given two different antihy-
perglycaemic drugs as initial treatment.
After 2.7 years, 39% of the patients on initial sulpho-
 




Oral blood glucose-lowering drugs
 
Biguanides A10BA02 Metformin
Sulphonylureas (SU) A10BB01 Glibenclamide








-Glucosidase inhibitors A10BF01 Acarbose
Thiazolidinediones (TZD) A10BG02 Rosiglitazone
A10BG03 Pioglitazone
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nylurea treatment had received follow-up treatment with
metformin, whereas 52% of initial metformin users had
received follow-up treatment with sulphonylurea. In 20–
38% of the patients on initial metformin treatment,
follow-up treatment with a sulphonylurea was already
started within the first 100 days (Figure 3A,C), whereas
follow-up treatment with metformin was more gradual
over the whole study period (Figure 3B,D).
Especially females in the 2000 cohort on initial met-
formin treatment were less likely to receive sulphony-
lurea in the follow-up period compared with the 1998








 0.003). In both year cohorts,
10% of the males and 25% of the females discontinued
using metformin after receiving follow-up treatment with
a sulphonylurea, which could not be attributed to any
differences in prescribed dosages of metformin (data not
shown). The initial users of sulphonylurea in the 2000
cohort were more likely to receive metformin compared






 0.007). No difference was
found between males and females (Figure 3B,D). In 10%
of the cases, the sulphonylurea was discontinued after
follow-up treatment with metformin was started.
Age differences between the cohorts were only small
and did not influence the differences found.
At the end of the follow-up period, about 8% of the
initial metformin and initial sulphonylurea users had
started with insulin (data not shown). No earlier switch
to insulin was found between the year or gender cohorts,
but there was a difference in discontinuation rates of the
initial drug. After receiving insulin, more patients dis-
continued using the sulphonylurea (70%) compared










Based on pharmacy dispensing data, we found an
increase in the prevalence and incidence rate of oral
antihyperglycaemic drug use over the period 1998–
2003. Changes in initial and follow-up prescription rates
of individual drugs were largely in agreement with new





 patients on initial treatment with
metformin increased from 15% in 1998 to 50% in 2003.
Furthermore, metformin was added more frequently to
initial sulphonylurea treatment in 2000 compared with
1998. The new drugs, thiazolidinediones and megli-
tinides, were seldom used as initial treatment.
Several studies have addressed changes in pharmaco-
logical treatment in diabetes over time. Some did not
focus on specific drug treatments [14, 15], included all
diabetes mellitus patients [9] or were based on data from
the early 1990s [15–17]. Those that did address treat-




Prevalence (A) and incidence (B) rate of oral antihyperglycaemic drug 
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Proportion of initial treatment with oral antihyperglycaemic drugs (drug 
groups are not mutually exclusive due to 2–3% of patients receiving two 
drugs at the date of initial treatment). The group ‘other’ includes acarbose, 
rosiglitazone, pioglitazone, repaglinide and insulin. Other ( ), 
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cation of the main UKPDS results showed that
metformin use increased after 1997 [8–11]. Our study
demonstrates that the rapid increase in metformin use
was largely due to the increased use of metformin as
initial treatment but also as follow-up treatment for
patients started on sulphonylurea, which is in accor-
dance with the revised guideline recommendations in
the Netherlands. The fact that the new drugs, marketed





prescribed as initial treatment is also in agreement with
the guideline recommendations. It can, however, be
expected that the extension of the registered indications
of the thiazolidinediones in Europe in 2004, allowing




 patients, will lead to
an increased use of these drugs as initial treatment. This
is analogous to the USA, where thiazolidinediones were
marketed earlier and had a broader registration at intro-
duction, and where a steep increase in their prescription
rates has been reported [8, 11].
Within the group of the sulphonylureas, the prescrip-
tion of glibenclamide and tolbutamide decreased during
the study period. Only the decreased use of glibencla-
mide is in accordance with the revised guidelines and
corresponds with observations in the UK that longer-
acting sulphonylureas are increasingly being replaced
by shorter-acting drugs [9, 10].
The observation that female patients discontinued
metformin more frequently than male patients when
receiving follow-up treatment with sulphonylurea is




Kaplan–Meier curves showing the changes in treatment after initial treatment with metformin in males (A) and females (B), and with sulphonylurea in 
 
males (C) and females (D)
Patients at risk
male male
1998 75 42 40 31 28 456 375 324 280 243
2000 130 83 70 60 52 436 338 281 232 195
1998 78 48 39 33 27 551 442 389 327 382
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dosages for metformin between males and females. The
discontinuation rate in females of 25% is much larger
than expected from tolerability data of clinical trials,
which showed that 10–15% of patients discontinued
metformin because of adverse effects [18].
A strength of this study is that the pharmacy dispens-
ing records were linked to individual patients. This
made it possible to follow individual drug use over time.
Prevalence data give insight only into the percentage of
the population exposed to oral antihyperglycaemic
drugs in a given period of time. The incidence and
follow-up prescription rates give a better insight into the
drug preferences of doctors in specific time periods.





 Pharmacy databases do not include
detailed clinical information. Therefore, it is not known
whether the observed prescription rates for metformin
fully followed the revised guideline with respect to the
prevailing BMI. On the other hand, the proportion of















 in the Neth-
erlands [19, 20].
Second, we recognize that there is a small overlap
between the two year cohorts, which tends to result in
an underestimation.
In conclusion, we found a significant change in the
prescribing pattern of oral antihyperglycaemic drugs in
patients with T2DM which was in concordance with the
publication of the UKPDS results and practice guideline
revisions in the Netherlands. This indicates that in this
therapeutic area changes in insights and treatment rec-
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